Evusheld vaccine to be submitted to NICE for appraisal.
The UK government has decided not to buy the COVID preventative injection Evusheld for immunocompromised people in the UK
The decision has come as a surprise and a huge disappointment to many doctors, charities, and campaign groups who signed an expert consensus statement on August 1 for the Government to make the drug available. The prophylactic monoclonal antibody treatment was seen as a lifeline for the thousands of immunocompromised people still shielding from COVID-19.
The Department for Health and Social Care has agreed with AstraZeneca that Evusheld will be submitted for a full NICE appraisal. Evusheld was approved by the MHRA in March 2022 and is now available in 32 countries, including the US, Israel, and parts of Europe. It is used to prevent COVID in those who are unlikely to have had a response to the COVID-19 vaccines, including those who are immunocompromised.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.